Evidence map›Paper›PMID 34776242›Full record

ArticleGynecologic oncology2022

Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.

Lilah Khoja, Rachel Palmieri Weber, Australian Ovarian Cancer Study Group, Penelope M Webb, Susan J Jordan, Aruna Muthukumar, Jenny Chang-Claude, Renée T Fortner, Allan Jensen, Susanne K Kjaer and 21 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Global epidemiology of epithelial ovarian cancer.Nature reviews. Clinical oncology · 2024
    Review
  4. Review
  5. Endometriosis and menopause-management strategies based on clinical scenarios.Acta obstetricia et gynecologica Scandinavica · 2023
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 19 institutions in 5 countries.

Lilah KhojaDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: lkhoja@umich.edu.
Rachel Palmieri WeberDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC 27705, USA. Electronic address: rachel.weber@epividian.com.
Australian Ovarian Cancer Study Group
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia. Electronic address: penny.webb@qimrberghofer.edu.au.
Susan J JordanSchool of Public Health, The University of Queensland, Brisbane, Queensland 4006, Australia. Electronic address: s.jordan@uq.edu.au.
Aruna MuthukumarDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: arumuthu@umich.edu.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: j.chang-claude@dkfz.de.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: r.fortner@dkfz-heidelberg.de.
Allan JensenDepartment of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, DK-2100, Denmark. Electronic address: allan@cancer.dk.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, DK-2100, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, DK-2100, Denmark. Electronic address: susanne@cancer.dk.
Harvey RischChronic Disease Epidemiology, Yale School of Public Health, New Haven, CT 06510, USA. Electronic address: harvey.risch@yale.ed.
Jennifer Anne DohertyHuntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: Jen.Doherty@hci.utah.edu.
Holly R HarrisDepartment of Epidemiology, University of Washington, Seattle, WA 98195, USA; Program in Epidemiology, Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: hharris@fredhutch.org.
Marc T GoodmanCancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: Marc.Goodman@cshs.org.
Francesmary ModugnoWomen's Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, PA 15213, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: fm@cs.cmu.edu.
Kirsten MoysichDivision of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address: Moysich@roswellpark.org.
Andrew BerchuckDepartment of Gynecologic Oncology, Duke University Medical Center, Durham, NC 277170, USA. Electronic address: berch001@mc.duke.edu.
Joellen M SchildkrautEmory University Rollins School of Public Health, Atlanta, GA 30322, USA. Electronic address: joellen.m.schildkraut@emory.edu.
Daniel CramerDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: dcramer@bwh.harvard.edu.
Kathryn L TerryDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: kterry@bwh.harvard.edu.
Hoda Anton-CulverDepartment of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA 92617, USA. Electronic address: hantoncu@hs.uci.edu.
Argyrios ZiogasDepartment of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA 92617, USA. Electronic address: aziogas@uci.edu.
Minh Tung PhungDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: phungmt@umich.edu.
Gillian E HanleyDepartment of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: gillian.hanley@vch.ca.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA. Electronic address: anna.wu@med.usc.edu.
Bhramar MukherjeeDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: bhramar@umich.edu.
Karen McLeanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. Electronic address: karenmcl@umich.edu.
Kathleen ChoDepartment of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. Electronic address: kathcho@med.umich.edu.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: pikem@mskcc.org.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. Electronic address: lpearce@umich.edu.
Alice W LeeDepartment of Public Health, California State University, Fullerton, CA 92831, USA. Electronic address: alicelee@fullerton.edu.
University of Michigan · USBrigham and Women's Hospital · USDuke Medical Center · USHeidelberg University · DEUniversity of California, Irvine · USUniversity of Southern California · USCalifornia State University, Fullerton · USCedars-Sinai Medical Center · USDanish Cancer Society · DKEmory University · USFred Hutch Cancer Center · USQIMR Berghofer Medical Research Institute · AURoswell Park Comprehensive Cancer Center · USThe University of Queensland · AUUniversity of British Columbia · CAUniversity of Copenhagen · DKUniversity of Utah · USUPMC Hillman Cancer Center · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
RB-RELATED PROTEINS IN SV4OT AND E1A TRANSFORMATIONR01CA063113 · NCI · DANA-FARBER CANCER INSTITUTE · PI DECAPRIO, JAMES A. · 1994 to 2018
$5.0M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Epidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5M
Steroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3M
HEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESR01CA058860 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANTON-CULVER, HODA A · 1994 to 2008
$3.1M
NCI NIH HHS N01 CN025403NCI NIH HHS N01 CN25524NCI NIH HHS N01 PC067006NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA105009NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063113NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA112523NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195
6 · The paper itself

Abstract

objectiveTo evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.

methodsWe conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs).

resultsOverall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99).

conclusionsThe hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation.

Indexed as

EndometriosisEstrogen Replacement TherapyHysterectomyMenopauseOvarian NeoplasmsCase-Control StudiesFemaleHumansEndometriosisHormone therapyHysterectomyOvarian cancer

Identifiers

PMID34776242
PMCPMC9444325
OpenAlexW3211375066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.